New drug developments for patients with metastatic soft tissue sarcoma

被引：8

作者：

Hartmann J.T. ^{[1
]}

Patel S. ^{[1
]}

机构：

[1] Department of Hematology/Oncology/Immunology/Rheumatology, UKT-Medical Center II, Eberhard-Karls-University Tuebingen, 72076 Tuebingen

来源：

Current Oncology Reports | 2005年 / 7卷 / 4期

关键词：

Sarcoma; Docetaxel; Gemcitabine; Clin Oncol; Soft Tissue Sarcoma;

D O I：

10.1007/s11912-005-0054-5

中图分类号：

学科分类号：

摘要：

For the subgroup of patients with inoperable gastrointestinal stromal tumors, progress has been made by the rapid development and approval of the targeted therapy imatinib mesylate. Small round cell sarcomas (SRCT), such as Ewing/primitive neuroectodermal tumor, desmoplastic SRCT, and rhabdomyosarcoma, are chemotherapy-sensitive and potentially curable malignancies that are treated with multimodality dose-intensive neoadjuvant protocols regardless of size or overt metastatic disease. However, the number of effective cytotoxic agents for the treatment of patients with metastatic so-called adult soft tissue sarcoma is limited, especially when patients have failed anthracycline- and ifosfamide-based chemotherapy. Copyright © 2005 by Current Science Inc.

引用

页码：300 / 306

页数：6

共 59 条

[1]

Patel S.R., New agents in the treatment of soft-tissue sarcomas, Expert Opin. Investig. Drugs, 9, pp. 1545-1551, (2000)

[2]

Patel S.R., Chu P., Vadhan-Raj S., Differential responsiveness of leiomyosarcoma (leio) arising at different sites to doxorubicin-based chemotherapy, Proc. Am. Assoc. Cancer Res., 38, (1997)

[3]

Bertuzzi A., Castagna L., Nozza A., Et al., High-dose chemotherapy in poor-prognosis adult small round-cell tumors: Clinical and molecular results from a prospective study, J. Clin. Oncol., 20, pp. 2181-2188, (2002)

[4]

Kushner B.H., LaQuaglia M.P., Wollner N., Et al., Desmoplastic small round-cell tumor: Prolonged progression-free survival with aggressive multimodality therapy, J. Clin. Oncol., 14, pp. 1526-1531, (1996)

[5]

Borden E.C., Amato D.A., Rosenbaum C., Et al., Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas, J. Clin. Oncol., 5, pp. 840-850, (1987)

[6]

Lopez M., Vici P., Di Lauro L., Carpano S., Increasing single epirubicin doses in advanced soft tissue sarcomas, J. Clin. Oncol., 20, pp. 1329-1334, (2002)

[7]

Cure H., Krakowski I., Adenis A., Et al., Results of a phase II trial with second-line cystemustine at 60 mg/m2 in advanced soft tissue sarcoma: A trial of the EORTC Early Clinical Studies Group, Eur. J. Cancer, 34, pp. 422-423, (1998)

[8]

Bramwell V.H., Anderson D., Charette M.L., Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma, Cochrane Database Syst. Rev., (2003)

[9]

Benjamin R.S., Legha S.S., Patel S.R., Nicaise C., Single-agent ifosfamide studies in sarcomas of soft tissue and bone: The M.D. Anderson experience, Cancer Chemother. Pharmacol., 31, SUPPL. 2, (1993)

[10]

Gottlieb J.A., Benjamin R.S., Baker L.H., Et al., Role of DTIC (NSC-45388) in the chemotherapy of sarcomas, Cancer Treat. Rep., 60, pp. 199-203, (1976)

← 1 2 3 4 5 6 →